Merck & Co. Inc.
MRKBusiness Overview
ticker: MRK step: 01 generated: 2026-05-11 source: quick-research
Merck & Co., Inc. (MRK) — Business Overview
Business Description
Merck is one of the world's largest pharmaceutical companies, anchored by Keytruda (pembrolizumab) — the best-selling oncology drug in history ($29.5B in 2024 sales, projected ~$32.7B peak in 2026). The company sells branded pharmaceuticals, vaccines, and animal health products globally. Merck's strategic identity for 2026–28 is dominated by one question: how does it absorb the Keytruda patent cliff in 2028? Management is responding through (1) Keytruda subcutaneous (Keytruda QLEX) for IV-to-SC conversion, (2) splitting oncology into a standalone business unit, (3) aggressive M&A ($10B Verona + $6.7B Terns + smaller deals), and (4) accelerating WINREVAIR (PAH) and other pipeline launches.
Revenue Model
Single reportable segment ("Pharmaceutical"), but with several franchise groupings:
- Oncology — Keytruda (~45% of total revenue), Welireg, Lynparza (royalty from AZ partnership), Lenvima (royalty), and pipeline.
- Vaccines — Gardasil/Gardasil 9 (HPV), Pneumovax, ProQuad (MMRV), Vaxneuvance, Capvaxive (pneumococcal), Rotateq.
- Cardiovascular / Pulmonary — WINREVAIR (PAH), Ohtuvayre (COPD, post-Verona acquisition), Adempas (royalty), Verquvo, Bridion.
- Diabetes / Hospital Acute Care — Januvia/Janumet (off-patent), Bridion, Zerbaxa, Inhalation anesthesia.
- Antiviral / Other — Lagevrio (Covid), Isentress, Pifeltro.
- Animal Health — Companion animal + livestock pharmaceuticals (Bravecto, vaccines).
Revenue mix is heavily skewed to Keytruda — the single largest concentration risk in mega-cap pharma.
Products & Services
- Keytruda — PD-1 inhibitor approved in 40+ indications across 20+ tumor types; the cornerstone oncology asset.
- Keytruda QLEX — Subcutaneous pembrolizumab formulation (FDA approved); aims for 30–40% conversion by 2028.
- Welireg (HIF-2α) — Newer oncology asset (renal cell carcinoma).
- Gardasil 9 — HPV vaccine; China shipment freeze in 2025 was a multi-quarter drag.
- WINREVAIR — PAH (activin inhibitor); 12-yr US biologics exclusivity (potentially to 2037); $419M in 2024, ramping toward $5–10B peak.
- Ohtuvayre (ensifentrine) — First-in-class COPD maintenance; potential blockbuster from Verona acquisition (closed late 2025).
- Pipeline (selected): TIGIT/PD-1 (vibostolimab), MK-7264 (TL1A IBD), oral PCSK9 (Eylea-class), Terns CML asset, plus oncology pipeline rebuilding.
Customer Base & Go-to-Market
- Oncology: Hospitals, academic medical centers, oncology specialty pharmacies. ~30,000+ sales reps globally.
- Vaccines: Governments (Gardasil school-age programs), pediatricians, pharmacies, employers; large public-tender dependency.
- Animal Health: Veterinary clinics, livestock producers; distributed through veterinary distributors.
- Geography: ~50% US, ~50% international. China is critical for Gardasil (recovering); EU/Japan/EM for Keytruda and other oncology.
Competitive Position
- Oncology — Keytruda is the dominant PD-1 globally (~70%+ market share among PD-1s); Opdivo (BMS) is the primary competitor. Pipeline gap relative to competitors (Roche tiragolumab, BMS Opdivo subQ + relatlimab combo, AstraZeneca Imfinzi, Daiichi/AZ DXd ADCs) is the single biggest structural issue.
- Vaccines — Gardasil 9 is the global standard for HPV; ProQuad/MMR-V are best-in-class for childhood vaccines; new Capvaxive pneumococcal targets adults.
- PAH — WINREVAIR is best-in-class entry; competing with Opsumit (J&J) and Uptravi (J&J) but with novel MOA.
- Animal Health — Top 3 globally with Zoetis and Elanco.
Structural risks: (1) Keytruda 2028 patent cliff (US composition-of-matter expires); (2) ~$25B+ revenue at risk over 2028–32; (3) pipeline depth vs. peers; (4) IRA Medicare price negotiations expanded to more drugs starting 2026.
Key Facts
- Founded: 1891
- Headquarters: Rahway, New Jersey
- Employees: ~71,000
- Exchange: NYSE
- Sector / Industry: Health Care / Pharmaceuticals
- Market Cap: ~$200B
- 2024 Revenue: $64.2B
- 2025 Revenue Guide: $64.1–65.6B
- Major Acquisitions Recent: Verona Pharma ($10B, Ohtuvayre COPD); Terns Pharma ($6.7B, CML); Prometheus ($10.8B, MK-7240 TL1A); Acceleron ($11.5B, WINREVAIR predecessor)
Financial Snapshot
ticker: MRK step: 04 generated: 2026-05-11 source: quick-research
Merck & Co., Inc. (MRK) — Financial Snapshot
Income Statement Summary
| Metric | FY2023 | FY2024 | FY2025 | YoY (FY25) |
|---|---|---|---|---|
| Revenue | $60.1B | $64.2B | $65.0B | +1.3% |
| Keytruda Revenue | $25.0B | $29.5B | $31.7B | +7% |
| Adjusted Operating Margin | ~40% | ~42% | ~43% | +100 bps |
| GAAP EPS | $0.14* | $6.74 | $7.28 | +8% |
| Adjusted EPS | $6.74 | $7.65 | $8.98 | +17% |
*FY2023 GAAP EPS depressed by ~$10B Prometheus + ~$5.5B Daiichi-Sankyo IPR&D charges.
Top Products (FY2025)
| Product | FY25 Sales | YoY | Notes |
|---|---|---|---|
| Keytruda + Keytruda QLEX | $31.7B | +7% | QLEX SC contributed $35M in Q4 (early launch) |
| Gardasil 9 | ~$8.2B | -5% | China shipment freeze pressure |
| WINREVAIR (PAH) | $1.4B | NM | Ramping toward multi-billion peak |
| Animal Health | $6.4B | +8% | Strong companion + livestock |
| Lagevrio (Covid) | declining | NM | Endemic phase |
Cash Flow & Balance Sheet (FY2025)
| Metric | Value |
|---|---|
| Operating Cash Flow | ~$18B |
| Capital Expenditures | ~$5B |
| Free Cash Flow | $12.4B (FY25) |
| Free Cash Flow Target (FY27) | ~$24B |
| Dividend (Quarterly) | $0.81 |
| Annual Dividend Yield | ~2.9% |
| Dividend Payout Ratio | ~44% (earnings); ~68% (cash) |
| Cash & Marketable Securities | ~$13B |
| Total Debt | ~$36B |
| Major Recent Acquisitions | Verona ($10B), Terns ($6.7B), Cidara (~$9B charge in Q1 2026) |
Key Ratios (approximate)
- P/E: ~9x (FY25 adjusted EPS) | EV/EBITDA: ~8x | FCF Yield: ~6% (depressed by IPR&D charges)
- Revenue Growth (FY25): +1.3% | Adjusted EPS Growth: +17%
- Dividend Yield: ~2.9%; payout ratio ~44% of earnings
- Operating Margin: ~43% (adjusted)
Growth Profile
2025 was the last "clean" year before the 2028 Keytruda patent cliff dominates the narrative. Revenue +1.3% nominally (Gardasil China + Lagevrio Covid both significant drags); adjusted EPS +17% on operating leverage and lower charges. Key forward dynamics:
2026–27: Keytruda continues growing toward ~$32B+ peak (2026); Keytruda QLEX (subcutaneous) launching to convert IV patients ahead of biosimilars. WINREVAIR ramping; Ohtuvayre (from Verona) launching; pipeline asset readouts. ~$24B FCF target for 2027.
2028+: Keytruda US loss of exclusivity. Bear case: ~50%+ of Keytruda IV revenue lost over 2028–32 to biosimilars; revenue declines 15–25% from peak. Bull case: 30–40% conversion to Keytruda QLEX (12-yr biologic exclusivity) preserves $9–12B; pipeline (WINREVAIR, Ohtuvayre, MK-7240 TL1A, Terns CML, oral PCSK9) replaces lost revenue.
Forward Estimates
2026 Guide (initial):
- Revenue: $65.5–67B (vs. $67.6B consensus — modest miss)
- Adjusted EPS: $5.00–5.15 (vs. $5.36 consensus — includes ~$3.65 one-time Cidara acquisition charge)
- Underlying EPS (ex-Cidara charge): $8.65–8.80, roughly flat YoY
Sell-side estimates have material divergence on 2028+. Bull case: $24B+ FCF / share at 2027 trough, recovery to growth by 2030 via pipeline. Bear case: 2028–30 trough in EPS at ~$5–6/share with multiple compression to ~8x P/E.
Deeper Financial Analysis
The fundamental tier adds 9 additional research dimensions for $MRK.